Elicio Therapeutics, Inc.
NASDAQ:ELTXBiotechnology
-$0.89 today
- Market cap
- $51.48M
- Beta
- 1.14
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$2.21
Volume 0.41M
Average 0.34M
ELTX Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Elicio Therapeutics, Inc.NASDAQ: ELTX
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments remains negative
Q1 FY2026 short-term investments was $0, compared with $0 a year earlier.
Context
- Short-term investments amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Short-term investments increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How ELTX compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Short-term investments amounts to 0.0% of total assets for ELTX, versus a peer median of 58.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $203.07M USD | -4.6% | -9.1% | 54.6% | |
| Mar 2026 | $112.9M USD | +938.3% | -16.7% | 58.3% | |
| Mar 2026 | $112.56M USD | -1.2% | +47.3% | 77.9% | |
| Mar 2026 | $90.15M USD | +66.5% | — | 57.7% | |
| Mar 2026 | $37.51M USD | -32.8% | -22.8% | 76.3% | |
| Mar 2026 | $33.76M USD | +487.9% | -24.2% | 65.1% | |
| Mar 2026 | CHF 14.52M CHF | -70.7% | -59.9% | 16.6% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
ACTUActuate Therapeutics Inc | Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding ELTX) | — | -1.2% | -19.8% | 58.0% | |
Competitors are the stored peer set for ELTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 88.76M | 7.8M | 12.89M | 17.62M | 18.56M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 806K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 379K | 36K | 895K | 1.28M | 73K |
| Total Current Assets | 91.25M | 10.72M | 16.35M | 20.69M | 19.31M |
| Property, Plant & Equipment (Net) | 4.44M | 8.5M | 7.28M | 6.19M | 5.08M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 723K | 617K | 0 | 696K | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 106K | 2.83M | 3.52M | 600K | 1.47M |
| Total Non-current Assets | 5.27M | 11.95M | 10.8M | 7.49M | 6.55M |
| Total Assets | 96.51M | 22.66M | 27.15M | 28.18M | 25.86M |
| Account Payables | 4.71M | 2.81M | 4.37M | 1.04M | 672K |
| Short-term Debt | 952K | 692K | 0 | 901K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.3M | 1.44M | 0 | 1.17M | 0 |
| Other Current Liabilities | 2.06M | 444K | 2.57M | 2.31M | 2.53M |
| Total Current Liabilities | 11.3M | 6.87M | 9.76M | 11.52M | 8.11M |
| Long-term Debt | 0 | 0 | 0 | 20.03M | 9.41M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 92K | 11K | 2.83M | 2.62M |
| Total Non-current Liabilities | 3.71M | 6.88M | 6.02M | 27.97M | 16.12M |
| Total Liabilities | 15.01M | 13.75M | 15.77M | 39.49M | 24.23M |
| Common Stock | 300K | 3K | 96K | 110K | 178K |
| Retained Earnings | (215.14M) | (107.01M) | (142.2M) | (194.1M) | (233.67M) |
| Accumulated OCI | (103K) | 0 | (197K) | (175K) | (127K) |
| Other Stockholders Equity | 226.01M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 81.51M | 8.92M | 11.37M | (11.31M) | 1.64M |
| Total Debt | 4.66M | 7.48M | 6.92M | 26.04M | 14.51M |
| Net Debt | (84.09M) | (316K) | (5.98M) | 8.42M | (4.05M) |
Elicio Therapeutics, Inc.
NASDAQ:ELTX
Intrinsic Alpha fair value
Locked
Current Price
$2.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.